Cerus Corporation

NASDAQ:CERS

Medical - Devices

Healthcare
$1.94 +2.92%

+$0.08 today

Market cap
$391.79M
Beta
1.77
P/E (TTM)
-53.8
EPS (TTM)
-$0.05
52W Low $1.15High $3.15

Volume 6.09M

Average 2.33M

CERS EBITDA Margin

EBITDA as a percentage of revenue.

Cerus CorporationNASDAQ: CERS

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 1.3%

EBITDA Margin was 1.3% in Q1 FY2026, up 13.4 pp from a year earlier. On a trailing-twelve-month basis it was 0.5%, up 5.1 pp year over year. Over 3 fiscal years it widened by 18.3 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 2.1% for the fiscal year ending Dec 2026, up from -2.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
1.3%-0.5 pp QoQ
Last fiscal yearDec 2025
-2.4%+3.2 pp YoY
LTMMar 2026
0.5%+5.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+13.4 pp+5.2 pp-8.2 pp
1 year+3.2 pp+4.5 pp+1.3 pp
3 years+18.3 pp+8.5 pp-9.8 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-2.4%
Year-over-year change
+3.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CERS compares with its peers on the latest reported figures

  • CERS's LTM Mar 2026 EBITDA Margin of 0.5% is the lowest of the 4 companies compared; the peer median is 23.5%.
  • Its year-over-year change of +5.1 pp is the 2nd highest of 4, against a peer median of +1.4 pp.
  • Over three fiscal years its change of +18.3 pp compares with a peer median of +2.8 pp.
CERS Competitors Peer median
EBITDA Margin for CERS and competitors
Company Period LTM level YoY 3-year change
ADMAADMA Biologics, Inc.LTM Jun 202645.5% +11.1 pp+64.4 pp
GRFSGrifols, S.A.LTM Jun 202623.5% +1.4 pp+2.8 pp
HAEHaemonetics CorporationLTM Jun 202619.3% -8.7 pp-2.2 pp
CERSCerus CorporationLTM Mar 20260.5% +5.1 pp+18.3 pp
Peer median (excluding CERS) 23.5%+1.4 pp+2.8 pp

Competitors are the stored peer set for CERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.86M162.05M156.37M180.27M206.13M
Cost of Revenue63.48M74.95M69.97M80.75M95.85M
Gross Profit67.38M87.09M86.4M99.52M110.29M
Gross Margin51.5%53.7%55.3%55.2%53.5%
Research & Development63.69M64.11M67.64M58.91M65.72M
Selling, General & Admin81.29M83.34M75.52M75.89M80.91M
Operating Expenses116.32M121.18M116.45M113.75M146.63M
Depreciation & Amortization3.15M2.98M2.6M1.86M2M
EBITDA(45.99M)(33.52M)(26.34M)(10.02M)(4.94M)
EBITDA Margin-35.1%-20.7%-16.8%-5.6%-2.4%
Operating Income(48.94M)(34.08M)(30.05M)(14.23M)(36.35M)
Operating Margin-37.4%-21.0%-19.2%-7.9%-17.6%
Interest Income00000
Interest Expense4.92M5.83M8.39M8.88M8.34M
Other Income / Expenses(5.12M)(8.26M)(7.27M)(6.53M)21.06M
Income Before Tax(54.06M)(42.34M)(37.32M)(20.76M)(15.28M)
Pre-Tax Margin-41.3%-26.1%-23.9%-11.5%-7.4%
Income Tax Expense319K488K325K205K354K
Net Income(54.37M)(42.78M)(37.49M)(20.92M)(15.63M)
Net Margin-41.6%-26.4%-24.0%-11.6%-7.6%
EPS (Basic)(0.32)(0.24)(0.21)(0.11)(0.08)
EPS (Diluted)(0.32)(0.24)(0.21)(0.11)(0.08)
Weighted Avg Shares171.28M176.55M180.27M184.56M190.59M
Weighted Avg Shares (Diluted)171.28M176.55M180.27M184.56M190.59M

Cerus Corporation

NASDAQ:CERS

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.